|
| | Tosufloxacin Basic information |
| Product Name: | Tosufloxacin | | Synonyms: | 7-(3-Aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;Tosufloxacin;Tosufloxacin Tosyiate;7-(3-Amino-1-pyrrolidinyl)-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic Acid;dl-Tosufloxacin;TOSUFLOXACIN(SUBJECTTOPATENTFREE);Tosufloxacin USP/EP/BP;4-difluorophenyl)-6-fluoro-4-oxo-1 | | CAS: | 108138-46-1 | | MF: | C19H15F3N4O3 | | MW: | 404.34 | | EINECS: | | | Product Categories: | Tosufloxacin;Active Pharmaceutical Ingredients | | Mol File: | 108138-46-1.mol |  |
| | Tosufloxacin Chemical Properties |
| | Tosufloxacin Usage And Synthesis |
| Uses | Tosufloxacin Tosilate (CAS# 100490-36-6) was identified in a Haemophilus influenza clone ST422. | | Definition | ChEBI: 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid is a 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively. It is a 1,8-naphthyridine derivative, an amino acid, a monocarboxylic acid, an organofluorine compound, an aminopyrrolidine, a tertiary amino compound, a primary amino compound and a quinolone antibiotic. It is a conjugate base of a 1-[6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]pyrrolidin-3-aminium. | | Brand name | Tosufloxacin Tosilate is JAN. | | Pharmaceutical Applications | It is active against a wide range of Gram-positive and Gram-negative bacteria, including Acinetobacter spp., L. pneumophila and Campylobacter spp. Unlike many quinolones it is moderately active against L. monocytogenes. C. trachomatis is also moderately susceptible. It is active against some anaerobes, including the B. fragilis group. Activity against Mycobacterium spp. is limited. It is well absorbed by the oral route, achieving a plasma concentration of c. 1 mg/L 4 h after a 300 mg dose. Around 30–35% of the dose is eliminated in the urine, with an apparent elimination half-life of 6–7 h.
Clinical experience is limited, but high clinical and bacteriological cure rates have been obtained in patients with skin and soft-tissue infections. |
| | Tosufloxacin Preparation Products And Raw materials |
|
